Projects per year
Inappropriate Environmental Risk Assessment (ERA) and lack of compatible, comprehensive and sensitive analytical methods to study the fate and biological effects of cPACs at enantiomeric level is by far the biggest obstacle in unveiling the importance of enantiomerism of pollutants. This talk will introduce the phenomenon of chirality in the context of fate and effects of chiral PACs and their analysis in the environment. Results from our large-scale UK and European monitoring studies and lab scale microcosms will be presented and implications of enantiomer-dependant fate and ecotoxicity of cPACs for procedures applied in environmental risk assessment will be explored.
 Guideline on the ERA of medicinal products for human use; European Medicines Agency, Doc. Ref. MEA/CHMP/SWP/4447/00
 ERA for Veterinary Medicinal Products other than GMO containing and Immunological Products; EU Directive 81/852/EEC
|Title of host publication||EUROANALYSIS 2017|
|Publication status||Published - 30 Aug 2017|
|Event||EUROANALYSIS 2017 - Stockholm, Sweden|
Duration: 28 Aug 2017 → 1 Sep 2017
|Period||28/08/17 → 1/09/17|
FingerprintDive into the research topics of 'Stereoisomerism in environmental cycle of pharmacologically active compounds: a new paradigm in environmental (bio)analysis and risk assessment'. Together they form a unique fingerprint.
- 7 Finished
Environmental life-cycle of pharmacologically active compounds: new (bio)analytical approaches and environmental risk assessment
1/10/14 → 30/09/18
Project: Research council